{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:32:32Z","timestamp":1783110752131,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T00:00:00Z","timestamp":1514592000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Chang Gung Memorial Hospital Grants","award":["CMRPG3E0521~-2 and CMRPG3F0191~3"],"award-info":[{"award-number":["CMRPG3E0521~-2 and CMRPG3F0191~3"]}]},{"name":"National Science Council Research","award":["104-2314-B-182A-100-MY2"],"award-info":[{"award-number":["104-2314-B-182A-100-MY2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00417-017-3878-4","type":"journal-article","created":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T06:08:07Z","timestamp":1514614087000},"page":"479-487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity"],"prefix":"10.1007","volume":"256","author":[{"given":"Chung-Ying","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyin","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Ning","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tun-Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih-Shiou","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,30]]},"reference":[{"key":"3878_CR1","first-page":"290","volume":"37","author":"J Stone","year":"1996","unstructured":"Stone J, Chan-Ling T, Pe'er J et al (1996) Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 37:290\u2013299","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3878_CR2","first-page":"228","volume":"6","author":"FM Mutlu","year":"2013","unstructured":"Mutlu FM, Sarici SU (2013) Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol 6:228\u2013236","journal-title":"Int J Ophthalmol"},{"key":"3878_CR3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","volume":"155","author":"WC Wu","year":"2013","unstructured":"Wu WC, Kuo HK, Yeh PT et al (2013) An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol 155:150\u2013158","journal-title":"Am J Ophthalmol"},{"key":"3878_CR4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) BEAT-ROP cooperative Group.Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603\u2013615","journal-title":"N Engl J Med"},{"key":"3878_CR5","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548","journal-title":"Ophthalmology"},{"key":"3878_CR6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","volume":"155","author":"DM Brown","year":"2013","unstructured":"Brown DM, Heier JS, Clark WL et al (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155:429\u2013437","journal-title":"Am J Ophthalmol"},{"key":"3878_CR7","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Do DV, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121:2247\u20132254","journal-title":"Ophthalmology"},{"key":"3878_CR8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","volume":"53","author":"AG Salman","year":"2015","unstructured":"Salman AG, Said AM (2015) Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity. Ophthalmic Res 53:15\u201320","journal-title":"Ophthalmic Res"},{"key":"3878_CR9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/187152811798104872","volume":"10","author":"MW Stewart","year":"2011","unstructured":"Stewart MW (2011) Aflibercept (VEGF trap-eye): the newest anti-VEGF drug. Inflamm Allergy Drug Targets 10:497\u2013508","journal-title":"Inflamm Allergy Drug Targets"},{"key":"3878_CR10","doi-asserted-by":"publisher","unstructured":"Sukgen EA, S\u00f6ker G, Ko\u00e7luk Y, G\u00fclek B (2017) Effect of intravitreal aflibercept on central retinal arterial blood flow in type 1 retinopathy of prematurity. Eur J Ophthalmol. https:\/\/doi.org\/10.5301\/ejo.5000938","DOI":"10.5301\/ejo.5000938"},{"key":"3878_CR11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","volume":"133","author":"WC Wu","year":"2015","unstructured":"Wu WC, Lien R, Liao PJ et al (2015) Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 133:391\u2013397","journal-title":"JAMA Ophthalmol"},{"key":"3878_CR12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","volume":"37","author":"WC Wu","year":"2017","unstructured":"Wu WC, Shih CA, Lien R et al (2017) Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina 37:694\u2013701","journal-title":"Retina"},{"key":"3878_CR13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ajo.2014.06.009","volume":"158","author":"X Wang","year":"2014","unstructured":"Wang X, Sawada T, Sawada O et al (2014) Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol 158:738\u2013744","journal-title":"Am J Ophthalmol"},{"key":"3878_CR14","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien R, Yu MH, Hsu KH et al (2016) Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS One 11:e0148019","journal-title":"PLoS One"},{"key":"3878_CR15","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00018-013-1283-7","volume":"70","author":"P Carmeliet","year":"2013","unstructured":"Carmeliet P, Ruiz de Almodovar C (2013) VEGF ligands and receptors:implications in neurodevelopment and neurodegeneration. Cell Mol Life Sci 70:1763\u20131778","journal-title":"Cell Mol Life Sci"},{"key":"3878_CR16","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/bjc.1998.158","volume":"77","author":"RE Banks","year":"1998","unstructured":"Banks RE, Forbes MA, Kinsey SE et al (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77:956\u2013964","journal-title":"Br J Cancer"},{"key":"3878_CR17","first-page":"3147","volume":"6","author":"ML George","year":"2000","unstructured":"George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI (2000) Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 6:3147\u20133152","journal-title":"Clin Cancer Res"},{"key":"3878_CR18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3748\/wjg.v11.i8.1167","volume":"11","author":"M Enjoji","year":"2005","unstructured":"Enjoji M, Nakamuta M, Yamaguchi K et al (2005) Clinical significance of serum levels of vascular endothelial growth factor and its receptor in biliary disease and carcinoma. World J Gastroenterol 11:1167\u20131171","journal-title":"World J Gastroenterol"},{"key":"3878_CR19","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment For Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Opthalmol 121:1684\u20131694","journal-title":"Arch Opthalmol"},{"key":"3878_CR20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H et al (2012) Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153:327\u2013333","journal-title":"Am J Ophthalmol"},{"key":"3878_CR21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/clinchem\/47.4.617","volume":"47","author":"W Jelkmann","year":"2001","unstructured":"Jelkmann W (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47:617\u2013623","journal-title":"Clin Chem"},{"key":"3878_CR22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1179\/102453309X12583347113456","volume":"15","author":"E Ergenekon","year":"2010","unstructured":"Ergenekon E, Bozkaya D, Goktas T et al (2010) Are serum nitric oxide and vascular endothelial growth factor levels affected by packed red blood cell transfusions? Hematology 15:170\u2013173","journal-title":"Hematology"},{"key":"3878_CR23","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","volume":"100","author":"AL Hard","year":"2011","unstructured":"Hard AL, Hellstrom A (2011) On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment: a review. Acta Paediatr 100:1523\u20131527","journal-title":"Acta Paediatr"},{"key":"3878_CR24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/IAE.0000000000001117","volume":"37","author":"N Yoshihara","year":"2017","unstructured":"Yoshihara N, Terasaki H, Shirasawa M et al (2017) Permeability and anti-vascular endothelial growth factor effects of bevacizumab, ranibizumab and aflibercept in polarized retinal pigment epithelial layer in vitro. Retina 37:179\u2013190","journal-title":"Retina"},{"key":"3878_CR25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/02713683.2016.1164190","volume":"42","author":"D Cam","year":"2016","unstructured":"Cam D, Berk AT, Micili SC et al (2016) Histological and Immunohistochemical retinal changes following the intravitreal injection of Aflibercept, bevacizumab and Ranibizumab in newborn rabbits. Curr Eye Res 42:315\u2013322","journal-title":"Curr Eye Res"},{"issue":"Suppl 1","key":"3878_CR26","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1517\/14712598.5.1.S37","volume":"5","author":"D Ternant","year":"2005","unstructured":"Ternant D, Paintaud G (2005) Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 5(Suppl 1):S37\u2013S47","journal-title":"Expert Opin Biol Ther"},{"key":"3878_CR27","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC et al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98:1636\u20131641","journal-title":"Br J Ophthalmol"},{"key":"3878_CR28","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC et al (2017) Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizuman, and ranibizumab. Retina 37:1847\u20131858","journal-title":"Retina"},{"key":"3878_CR29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000252970","volume":"97","author":"JV Been","year":"2010","unstructured":"Been JV, Zoer B, Kloosterboer N et al (2010) Pulmonary vascular endothelial growth factor expression and disaturated phospholipid content in a chicken model of hypoxia- induced fetal growth restriction. Neonatology 97:183\u2013189","journal-title":"Neonatology"},{"key":"3878_CR30","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","volume":"20","author":"HF Dvorak","year":"2002","unstructured":"Dvorak HF (2002) Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368\u20134380","journal-title":"J Clin Oncol"},{"key":"3878_CR31","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrc909","volume":"2","author":"N Ferrara","year":"2002","unstructured":"Ferrara N (2002) VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2:795\u2013803","journal-title":"Nat Rev Cancer"},{"key":"3878_CR32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581\u2013611","journal-title":"Endocr Rev"},{"key":"3878_CR33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000210671","volume":"42","author":"M Ishii","year":"2009","unstructured":"Ishii M, Tanaka E, Imaizumi T et al (2009) Local VEGF administration enhances healing of colonic anastomoses in a rabbit model. Eur Surg Res 42:249\u2013257","journal-title":"Eur Surg Res"},{"key":"3878_CR34","first-page":"512","volume":"10","author":"JR McColm","year":"2004","unstructured":"McColm JR, Geisen P, Hartnett ME (2004) VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis 10:512\u2013520","journal-title":"Mol Vis"},{"key":"3878_CR35","first-page":"105","volume":"1","author":"TL Young","year":"1997","unstructured":"Young TL, Anthony DC, Pierce E, Foley E, Smith LE (1997) Histopathology and vascular endothelial growth factor in untreated and diode laser-treatedretinopathy of prematurity. JAAPOS 1:105\u2013110","journal-title":"JAAPOS"},{"key":"3878_CR36","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/gt.2009.111","volume":"16","author":"SA Sakowski","year":"2009","unstructured":"Sakowski SA, Heavener SB, Lunn JS et al (2009) Neuroprotection using gene therapy to induce vascular endothelial growth factor-a expression. Gene Ther 16:1292\u20131299","journal-title":"Gene Ther"},{"key":"3878_CR37","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.jss.2008.11.007","volume":"159","author":"C Yamamoto","year":"2010","unstructured":"Yamamoto C, Yagi S, Hori T et al (2010) Significance of portal venous VEGF during liver regeneration after hepatectomy. J Surg Res 159:e37\u2013e43","journal-title":"J Surg Res"},{"key":"3878_CR38","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/35025215","volume":"407","author":"GD Yancopoulos","year":"2000","unstructured":"Yancopoulos GD, Davis S, Gale NW et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242\u2013248","journal-title":"Nature"},{"key":"3878_CR39","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.bbrc.2009.10.058","volume":"390","author":"D Zisa","year":"2009","unstructured":"Zisa D, Shabbir A, Suzuki G, Lee T (2009) Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair. Biochem Biophys Res Commun 390:834\u2013838","journal-title":"Biochem Biophys Res Commun"},{"key":"3878_CR40","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.ophtha.2008.12.023","volume":"116","author":"T Sato","year":"2009","unstructured":"Sato T, Kusaka S, Shimojo H, Fujikado T (2009) Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 116:1599\u20131603","journal-title":"Ophthalmology"},{"key":"3878_CR41","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","volume":"56","author":"L Kong","year":"2015","unstructured":"Kong L, Bhatt AR, Demny AB et al (2015) Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 56:956\u2013961","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3878_CR42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-0037-1615158","volume":"80","author":"U Wartiovaara","year":"1998","unstructured":"Wartiovaara U, Salven P, Mikkola H et al (1998) Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 80:171\u2013175","journal-title":"Thromb Haemost"},{"key":"3878_CR43","first-page":"H1054","volume":"275","author":"JP Maloney","year":"1998","unstructured":"Maloney JP, Silliman CC, Ambruso DR et al (1998) In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Phys 275:H1054\u2013H1061","journal-title":"Am J Phys"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-017-3878-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-017-3878-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-017-3878-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T02:22:16Z","timestamp":1603592536000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-017-3878-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,30]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["3878"],"URL":"https:\/\/doi.org\/10.1007\/s00417-017-3878-4","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,30]]}}}